Clinical trials: Neuron Degeneration
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
ALS (Amyotrophic Lateral Sclerosis)
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited.
- Trial name
- UNZUELUZON ALS (NCT07737977)
- Testing
- peripheral venous blood collection, collection of medical data related to patient care
- Where
- 2 sites in France, Spain
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Reproductive Disorder, Neurodegeneration
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome.
- Conditions
- Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
- Trial name
- NCT07224490
- Testing
- Kisspeptin 112-121
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stephanie B. Seminara, MD
Stroke
Effect of Transcranial Direct Current Stimulation (tDCS) on Post-stroke Patients on Neuromotor Recovery
The aim of the study is to evaluate whether a non-invasive brain stimulation technique (Transcranial Direct Current Stimulation) can influence the secondary neurodegeneration observed after a stroke (assessed based on serum…
- Trial name
- NCT05821816
- Testing
- tDCS, Conventional rehabilitative treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Neurodegeneration With Brain Iron Accumulation (NBIA)
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants.
Neurodegeneration with brain iron accumulation (NBIA) represent a group of rare neurodevelopmental diseases, genetically as well as phenotypically heterogeneous. The diagnosis is based on brain MRI.
- Trial name
- NBIA MITO (NCT05615571)
- Testing
- Establishment of mitochondrial markers, Sequencing tests
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
Parkinson Disease, Parkinson's
Serotonin Release in Premotor and Motor PD
In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease.
- Conditions
- Parkinson Disease, Parkinson's, Parkinson's Disease, Neurodegenerative Diseases
- Trial name
- FOX3 (NCT05516732)
- Testing
- Positron Emission Tomography (PET) scan using CIMBI-36 tracer, Magnetic Resonance Imaging (MRI) Scan, Positron Emission Tomography (PET) scan using DASB tracer
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- University of Exeter
Ischemic Stroke
Focal Cortical Atrophy After Myocardial Internal Capsule
Primary purpose of the trial is to demonstrate the arisen of focal cortical atrophy, localized in the ipsilateral primary motor area, measured in mm, three months after infarction of internal capsule.
- Trial name
- ACFI (NCT01862172)
- Testing
- Additional MRI
- Where
- France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Toulouse
Cerebral Small Vessel Disease
Biomarkers, Risk Assessment, Imaging, and Neurodegeneration in Cerebral Small Vessel Disease (BRAIN-CSVD)
The BRAIN-CSVD study is a single-center prospective cohort study focusing on cerebral small vessel disease (CSVD).Patients enrolled in this research will undergo assessments for vascular risk factors, cognitive and other…
- Trial name
- BRAIN-CSVD (NCT07093515)
- Testing
- No intervention
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Zhejiang Hospital
Multiple Sclerosis, Relapsing-Remitting
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
Alemtuzumab is the active agent of a drug called Lemtrada®. In the European Union, Lemtrada® is approved for the treatment of a particular form of multiple sclerosis (the so called relapsing remitting form).
- Trial name
- ALAIN01 (NCT02419378)
- Testing
- Alemtuzumab
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Muenster
Dementia With Lewy Bodies, Degeneration Nerves
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies.
Lewy Body Dementia (DLB) is the second most common type of neurodegenerative dementia and characterized by loss of cholinergic neurons in the cerebrum and possibly also internal organs.
- Conditions
- Dementia With Lewy Bodies, Degeneration Nerves, Positron-Emission Tomography, Acetylcholine
- Trial name
- NCT04291144
- Testing
- PET-CT using FEOBV, MRI-scan, Cognitive assessment
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Parkinson Disease, Parkinsonism
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive…
- Conditions
- Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive
- Trial name
- MTMD (NCT03076671)
- Testing
- Palliative Care
- Where
- 2 sites in United States
- Volunteers
- 783 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS
Beyond white matter pathology, grey matter damage is considered as a key player in disability onset and progression in Multiple Sclerosis (MS).
- Trial name
- FLUMA-SEP-T (NCT03825601)
- Testing
- PET with [11C]Flumazenil
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer Disease, Mild Cognitive Impairment
Study to Understand Novel Biomarkers in Researching Dementia
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- SUNBIRD (NCT06547099)
- Testing
- Clinical tau PET, Clinical amyloid test, Research blood collection
- Where
- United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Primary Progressive Aphasia, MCI
tDCS Intervention in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g.
- Conditions
- Primary Progressive Aphasia, MCI, FTD
- Trial name
- NCT02606422
- Testing
- Active HD-tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer's Disease, Seizures
Seizure Activity in Alzheimer's Disease
The main purpose of this research project is to study how seizure-like activity affects the blood flow in the brain of patients with Alzheimer's disease (AD).
- Trial name
- NCT01554683
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Beth Israel Deaconess Medical Center
Multiple Sclerosis
BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
The purpose of this study is to investigate new quantitative MRI-sequences for assessment of age-specific data for the prediction of brain aging.
- Trial name
- BrainAgeMS (NCT06221631)
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis, Parkinson Disease
Biomarkers of Synaptic Damage in Multiple Sclerosis
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit.
- Conditions
- Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
- Trial name
- NCT03217396
- Testing
- lumbar puncture
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Neuromed IRCCS
Normal Healthy Adults
Imaging Biomarkers of Neuroplasticity and Neurodegeneration in the Living Human Brain
Following our recently completed whole body dosimetry study for [18F] TRACK in 6 healthy control subjects, the objective of this project is to evaluate brain uptake, regional distribution and in vivo pharmacokinetics for [18F]…
- Trial name
- F18TRACK (NCT05427656)
- Testing
- [18F] TRACK, Measurement of Arterial Input Function
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Thiel, Alexander, M.D.